third generation glp 1 GLP-1 Drugs and the Physiology of Metabolic Health Effect of GLP-1-RA on target

In September 2024, Terns Pharmaceuticals announced positive results from its Phase 1 clinical trial for TERN-601, a once-daily oral GLP-1 receptor agonist aimed at treating obesity

Beyond weight loss and diabetes treatment, GLP-1 drugs like Ozempic and Wegovy have shown some early potential to treat drug and alcohol addiction

State-of-the-Art Facility Located in Bay Harbor Islands, HMS Plastic Surgery features a cutting-edge facility designed specifically for aesthetic and reconstructive procedures

"Update on FDA's ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity"